Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; Ribociclib (Primary) ; Capecitabine; Docetaxel; Gemcitabine; Paclitaxel; Vinorelbine; Vinorelbine
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms RIGHT Choice
  • Sponsors Novartis Healthcare; Novartis Pharmaceuticals

Most Recent Events

  • 25 Nov 2024 According to a Novartis Media Release, data from this study will be presented at 2024 San Antonio Breast Cancer Symposium.
  • 24 Oct 2023 Results of sub-group analysis by visceral crisis status were presented at the 48th European Society for Medical Oncology Congress.
  • 24 Oct 2023 Results of quality of analysis from the phase II RIGHT choice study presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top